Drug Maker to Pay Out $1.2 Billion in Risperdal Marketing Case
On behalf of Brown & Crouppen, P.C. posted in Defective Medications on Sunday, April 15, 2012
When consumers in St. Louis are told by drug manufacturers that one of their prescriptions will affect and help them in a specific way, they expect that message to be truthful. Unfortunately, that is not always the case. Those who take the medication Risperdal may have been subject to a misleading marketing campaign for the prescription drug.
Risperdal is prescribed by physicians as an antipsychotic medication. The problem with this particular drug is that the manufacturer, Johnson & Johnson, misled doctors and patients about the dangers associated with consuming the product.
Most recently, a state court reached a judgment against Johnson & Johnson for illegal and deceptive marketing practices. In total, the company will have to pay out $1.2 billion for violating the state’s consumer-protection statutes.
The latest case against the manufacturer is only one in a string of several across the country. Already, judgments against the company have been reached in three other states for Medicaid reimbursements and improperly prescribing the medication. Despite multiple victories for consumers, Johnson & Johnson insists that no patients were ever harmed by their actions and the way they marketed Risperdal.
Consumers have the right to know how the products they use will affect them, particularly if there are any adverse side-effects. Drug companies have a responsibility to sell their products in an honest fashion, rather than deceiving people by touting the benefits of a potentially dangerous medication.
Despite a flood of news about defective or dangerous drugs, it is very important for people in Missouri to stay abreast of reports on the medications they regularly use or may be prescribed in the future. Personal health and well-being may depend on being aware of a particular drug’s safety.
Source: The Wall Street Journal, “Arkansas Judge Orders J&J To Pay $1.2B Over Risperdal Marketing,” Peter Loftus, April 11, 2012